Review Article Published: 12 June 2023 Antibody–drug conjugates come of age in oncologyCharles Dumontet, Janice M. Reichert, Peter D. Senter, John M. Lambert & Alain Beck Nature Reviews Drug Discovery volume 22, pages 641–661 (2023)Cite this article ...
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of can...
The antibody drug conjugate MORAb2, consisting of farletuzumab paired with a cathepsin Bヽleavable linker and eribulin, targets folate receptor alpha (FRA), which is frequently overexpressed on various tumor types. MORAb2 was highly cytotoxic to FRA﹑ositive cells in vitro, with limited off‐...
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncol. 2021 Dec 1;7(12):1873-1881. doi:10.1001/jamaoncol.2021.3595. Zhang L, Ma Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in ...
A comprehensive review of key factors affecting the efficacy of antibody drug conjugate AnupamaSamantasinghar, ...Kyung HyunChoi, inBiomedicine & Pharmacotherapy, 2023 1Introduction Antibody Drug Conjugate(ADC) is an emerging class of potent biological drugs that combine a highly potent cytotoxic ...
抗体偶联药物(Antibody-Drug Conjugates,ADCs)将靶向抗体疗法与强效细胞毒性药物相结合,已成为肿瘤学领域的一项关键创新,其应用从血液肿瘤已经发展到实体瘤。以泌尿系统肿瘤为例,在尿路上皮癌中,世界范围内已经有3款ADCs获批上市。结合以下内容,我们一起对ADCs在泌尿系统恶性肿瘤中的临床研究进展进行了总结和展望。
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates 2023, Translational Lung Cancer Research Antibody-drug Conjugate Targets, Drugs, and Linkers 2022, Current Cancer Drug Targets ...
摩根士丹利在最近的一份研究报告中表示,个体化癌症疫苗和抗体药物偶联物(antibody-drug conjugate,ADC)将成为明年主要的癌症治疗生物技术创新之一,包括 Moderna (MRNA.US)、 默沙东 (MRK.US)和 阿斯利康 (AZ... 网页链接
Unlocking the potential of antibody–drug conjugates for cancer therapy Article 08 February 2021 Antibody–drug conjugates come of age in oncology Article 12 June 2023 Antibody drug conjugate: the “biological missile” for targeted cancer therapy Article Open access 22 March 2022 References...
Zhang, J. et al. Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours.NPJ Breast Cancer9, 28 (2023). ArticleCASPubMedPubMed CentralGoogle Scholar Zhu, Y., Liu, K., Wang, K. & Zhu, H. Treatment-related adverse events of antibody-drug conjuga...